V

Varian

Tech-enabled radiation oncology hardware and software

Head of Critical Care Marketing

Full-TimeUpdated on 10/23/2026
$266.9k - $367k+ Commission eligibility
Expert
Bachelor's, Master's, MBA
Remote in USA
Remote
Growth & MarketingMarketing Generalist & Management
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A bachelor's degree is required.
  • At least 15 years of progressive leadership experience in marketing, strategy, portfolio management, or commercial leadership within healthcare, diagnostics, medical technology, or life sciences.
  • Proven success developing and executing portfolio strategies that drive sustainable revenue growth, profitability, and market share expansion.
  • Demonstrated experience leading global product innovation, commercialization, and lifecycle management efforts.
  • Strong business and financial acumen, including experience using market and financial analytics to drive strategic investment decisions.
  • Experience leading global or regional teams in complex, matrixed organizations.
  • Experience working across multiple geographies and healthcare markets, with an understanding of regional market dynamics and customer needs.
  • The successful candidate must be able to work with controlled technology in accordance with US export control law.
Responsibilities
  • Define and lead the global marketing and portfolio strategy for the Critical Care business, aligned with enterprise priorities and regional market needs.
  • Drive portfolio prioritization, lifecycle management, and investment decisions to maximize long-term growth, profitability, and shareholder value.
  • Lead market assessment, customer segmentation, competitive analysis, and strategic planning to identify growth opportunities and inform business decisions.
  • Champion customer-centric decision-making by incorporating understanding of clinical workflows, healthcare economics, unmet needs, and evolving market dynamics.
  • Lead marketing strategy for new product development, ensuring customer and market insights are translated into differentiated innovation opportunities and prioritized investments.
  • Partner with R&D to shape portfolio roadmaps, product requirements, and innovation priorities that address future customer and market needs.
  • Guide business case development and investment decisions using financial, commercial, and strategic evaluation frameworks.
  • Drive launch planning and commercialization strategies to accelerate adoption and achieve business objectives.
  • Leverage market intelligence and financial metrics, including revenue growth, market share, gross profit, net present value, and profit-and-loss performance, to guide strategic decisions.
  • Lead forecasting, scenario planning, and performance management processes to optimize resource allocation and investment priorities.
  • Ensure marketing and portfolio strategies are supported by analytics, measurable outcomes, and clear return-on-investment expectations.
  • Partner with Finance to align forecasts, budgets, and long-range planning efforts.
  • Translate global strategy into scalable commercial frameworks, tools, messaging, and programs that enable consistent execution across regions.
  • Partner with regional marketing and commercial leaders to drive growth while balancing global consistency with local market requirements.
  • Own commercial performance outcomes and strategic growth initiatives, adjusting priorities as market conditions and competitive dynamics evolve.
  • Identify opportunities to leverage digital, artificial intelligence-enabled, and workflow innovations that enhance customer value and strengthen competitive differentiation.
  • Serve as an ambassador for the Critical Care business with key customers, thought leaders, industry associations, and strategic partners.
  • Represent the business at industry events and customer engagements to strengthen market position and identify emerging trends.
  • Foster strategic partnerships that expand market presence and accelerate growth opportunities.
  • Partner with R&D, Medical Affairs, Market Access, Regulatory, Quality, Supply Chain, and Commercial organizations to drive business outcomes and successful portfolio execution.
  • Lead and align stakeholders across a highly matrixed global organization, influencing decisions and driving accountability without direct authority.
  • Ensure value propositions are differentiated, evidence-based, and aligned with customer, clinical, and economic needs.
  • Build, lead, and develop a high-performing global marketing organization with strong strategic, analytical, and commercial capabilities.
  • Foster a culture of accountability, collaboration, innovation, and continuous improvement.
  • Coach and develop future leaders while strengthening organizational capabilities in portfolio management, commercialization, customer engagement, and strategic marketing.
Desired Qualifications
  • An MBA, advanced business degree, or relevant graduate degree is preferred.
  • Experience in critical care, point-of-care diagnostics, acute care testing, blood gas analysis, or adjacent healthcare markets is preferred.

About the company

Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

1948

Get referred to Varian

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded Varian up to $60 million in April 2026 for FLASH-RT.
  • FDA cleared TrueBeam for osteoarthritis in March 2026, opening a non-cancer market.
  • Telix collaboration and 2026 AI approvals expand Varian's clinical and software pipeline.

What critics are saying

  • RaySearch enabled online adaptive TrueBeam workflows in Belgium in May 2026, eroding software differentiation.
  • Elekta still attacks Varian's lead in adaptive radiotherapy and premium MR-guided care.
  • If FLASH and non-oncology bets fail by 2028, Varian becomes a commoditized linear-accelerator vendor.

What makes Varian unique

  • Siemens Healthineers gives Varian imaging, radiotherapy, and capital-sales integration globally.
  • Varian's 2026 CE-marked Eclipse AI contouring deepens workflow lock-in across planning.
  • TrueBeam, Halcyon, and Ethos create an installed-base moat hospitals rarely replace.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Holidays
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Wellness Program
  • 401(k) Retirement Plan

Growth & Insights and Company News

6 month growth

3%

1 year growth

3%

2 year growth

3%
Varex Imaging Corporation
Sep 14th, 2026
About Us | Varex Imaging Corporation

We strive to help customers become world-class system suppliers by strengthening their competitiveness and enabling them to bring products to market faster

MEDQOR
Apr 30th, 2026
Siemens Healthineers secures $83M to develop photon Flash radiotherapy for cancer treatment

Siemens Healthineers has received up to $60 million from the US Advanced Research Projects Agency for Health to develop photon Flash radiotherapy, with the company contributing an additional $23 million, totalling $83 million over five years. Flash photon therapy delivers radiotherapy more than 100 times faster than current technologies, aiming to reduce side effects and improve healthy tissue sparing. Unlike proton and electron beam platforms, which face scalability challenges, photon beams are the standard of care for over 50% of cancer patients. The project will build on existing C-arm linear accelerators to enable broader clinical access. Siemens Healthineers aims to transition ultra-high dose rate radiotherapy from experimental treatment into global standard of care within the five-year timeframe.

Business Wire
Mar 19th, 2026
Varian TrueBeam gets FDA clearance for low-dose radiotherapy to treat osteoarthritis

Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.

AuntMinnieEurope.com
Dec 10th, 2025
Telix and Varian enter research collaboration

Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.

AuntMinnie.com
Mar 28th, 2025
Varian, Embolx sign image-guided microcatheter agreement

Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.